Fig. 4

Combination therapies predicted and in vivo validation. a All predicted co-druggable interactions of the MS drugs models. Based on the subgroup models, the co-druggability of all 168 network interactions (X axis) was assessed using the co-druggability score, and those identified as co-druggable (see Fig. 1, Table 1 and main text) are shown. For each interaction (X-axis) the number of drugs (Y-axis) is shown, in which it was found to be co-druggable using the co-druggability criteria. b FTY network co-druggability: the case of FTY network co-druggability is shown as an example (red line: interactions predicted to be co-druggable). c In vivo validation of the combination FTY+TAK1-inhibitor in the EAE model. The graph shows the mean and the standard error of the clinical score for each group (n=7). Animals started treatment after disease onset (clinical score >1.0) and were randomized to each treatment and rated in a blinded manner. Stars show days significantly different from the same day with placebo